This article explores how challenges such as sequence optimization, immune activation and off-target effects are being addressed to enhance the safety, durability and efficacy of RNA therapeutics.
BOSTON--(BUSINESS WIRE)--Corsera Health, Inc., leading the future of cardiovascular health through prediction and prevention, today announced the filing of a clinical trial notification (CTN) to ...
Advancing a once-annual preventive RNAi medicine designed to reduce the two key drivers of cardiovascular disease: LDL-C and blood pressure Filed application for COR-1004, a novel siRNA targeting ...
STUART, Fla.--(BUSINESS WIRE)--Cognigenics, a pioneering company in RNA-based therapeutics for neuropsychiatric conditions and neurocognitive disorders, announced the publication of its latest ...
As nucleic acid–based therapeutics evolve and mature, so too must the analytical tools that are designed to characterize them. New microfluidic capillary electrophoresis (CE) methods that are designed ...
ST. LOUIS – Hepatitis B virus, a killer of more than one million people each year, is a notoriously wily virus, often lingering and resurfacing even after treatment. But, thanks to a new class of ...
An RNA interference (RNAi) molecule that selectively targets the KRAS G12V mutation could represent a key advance in the treatment of cancer associated with this oncogenic variant. Researchers at the ...
Silexion Therapeutics Corp (NASDAQ:SLXN) has announced breakthrough preclinical results for its next-generation RNA interference (RNAi) therapy, SIL204, showing potent anti-tumor effects across three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback